Accuray Incorporated is a radiation oncology company that develops, manufactures, sells, and supports precise, innovative tumor treatment solutions. Accuray's leading-edge technologies, including the CyberKnife® and Radixact® Systems, are designed to deliver advanced radiosurgery, stereotactic body radiation therapy (SBRT), intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy. These systems aim to expand the curative power of radiation therapy and improve the quality of life for cancer patients.
Corporate leadership, research and development, global operations management, and administrative functions for its worldwide activities in the radiation oncology sector.
Modern facility in Silicon Valley, likely equipped with advanced R&D labs, product demonstration suites for its CyberKnife and Radixact systems, and collaborative workspaces designed to foster innovation in medical technology.
A dynamic and innovative environment focused on advancing cancer treatment. Emphasis on collaboration, precision, and patient-centric solutions. Likely promotes continuous learning and professional growth in a high-tech medical field.
Serves as the central hub for Accuray's global strategy, product development, and market expansion in the competitive field of radiation oncology. Its Silicon Valley location provides access to top talent and a vibrant tech ecosystem.
Accuray supports global functions including sales, marketing, customer service and support, clinical training, research and development, and manufacturing. The company has a direct presence and an extensive distributor network across North America, Europe, Asia, Latin America, and other key international markets to provide advanced cancer treatment solutions and support to healthcare providers worldwide.
1310 Chesapeake Terrace
Sunnyvale
CA
USA
Address: Route de la Longeraie 9, 1110 Morges, Switzerland
To drive adoption and support of Accuray's technologies across the EMEIA region, ensuring localized customer service, market penetration, and compliance with regional standards.
Address: 3200 Deming Way Ste 150, Middleton, WI 53562, USA
Continued innovation, development, and production of specific Accuray radiotherapy systems, contributing to the company's global product portfolio and technological advancements.
Address: Accuray Medical Equipment (Chengdu) Co., Ltd., No. 8, Kexin Road, West Zone, Chengdu Hi-Tech Comprehensive Free Trade Zone, Chengdu, Sichuan Province, China
To cater to the growing demand for advanced cancer treatment technologies in China and the Asia-Pacific region, supporting local manufacturing, training, service, and market access initiatives.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Accuray' leadership includes:
Accuray has been backed by several prominent investors over the years, including:
Over the past 12-18 months, Accuray has made several key appointments to its senior leadership team, strengthening its financial, commercial, operational, and legal functions to support strategic growth and innovation in the radiation oncology market.
Discover the tools Accuray uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Accuray primarily uses the [first_initial][last]@accuray.com email format (e.g., jdoe@accuray.com). This is the most common pattern for corporate communications. Other formats might exist but are less frequent.
[first_initial][last]@accuray.com
Format
swinter@accuray.com
Example
85%
Success rate
Accuray Investor Relations • May 7, 2024
Accuray announced financial results for its third quarter of fiscal year 2024, ended March 31, 2024. The company reported total revenue of $101.7 million, provided updates on gross orders, and discussed progress on its product adoption and strategic initiatives, including the launch of its VitalHold™ technology on the Radixact System in Japan....more
Accuray Investor Relations • May 2, 2024
Accuray announced its advanced radiotherapy technologies, including the CyberKnife S7 and Radixact Systems with Synchrony® and VitalHold™, would be featured in various scientific presentations and discussions at the European Society for Radiotherapy and Oncology (ESTRO) 2024 meeting in Glasgow, Scotland....more
Accuray Investor Relations • February 20, 2024
Accuray highlighted a new peer-reviewed study published in 'Stereotactic and Functional Neurosurgery' demonstrating the long-term effectiveness and safety of its CyberKnife System for treating trigeminal neuralgia. The findings support the system's precision and non-invasive benefits for this debilitating pain condition....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Accuray, are just a search away.